Zogenix Inc (ZGNX) 8.18 $ZGNX
Zogenix Provides Corporate Update and Reports Second Quarter 2016 Financial Results
GlobeNewswire - Tue Aug 09, 3:01PM CDT
Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today provided a corporate update and announced financial results for the second quarter ended June 30, 2016.
ZGNX: 8.18 (-0.54)
Zogenix to Release Second Quarter 2016 Financial Results and Host Conference Call and Webcast on August 9
GlobeNewswire - Tue Aug 02, 7:00AM CDT
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that it will report its financial results for the second quarter ended June 30, 2016 after the market close, and will host a corporate update conference call and webcast on Tuesday, August 9, at 4:30 PM Eastern Time.
ZGNX: 8.18 (-0.54)
Zogenix Announces Initiation of Multi-National Phase 3 Clinical Trial for ZX008 in Dravet Syndrome
GlobeNewswire - Tue Jun 07, 7:00AM CDT
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced the initiation of the second Phase 3 clinical trial, a multi-national study (Study 1502), for the Company's lead product candidate, ZX008, as an adjunctive treatment of seizures in children with Dravet syndrome. ZX008 is designated as an orphan drug in both the U.S. and Europe, and received Fast Track designation in the U.S., for the treatment of Dravet syndrome.
ZGNX: 8.18 (-0.54)
Zogenix to Participate in Jefferies 2016 Healthcare Conference
GlobeNewswire - Tue May 31, 7:00AM CDT
Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, will present a corporate update at the Jefferies 2016 Healthcare Conference, which is being held in New York, NY, June 7-10, 2016.
ZGNX: 8.18 (-0.54)
Nordic Nanovector ASA: New Board Members Elected Bringing Further Expertise in the Development and Commercialization of Innovative Cancer Therapies
BusinessWire - Mon May 23, 12:17AM CDT
The annual general meeting of Nordic Nanovector ASA on 19 May elected two new board members, further strengthening the base of international experience as well as oncology/haematology, life science and commercialization expertise of the company's board. Dr Renee P Tannenbaum, Pharm. D and Jean-Pierre Bizzari, MD, were elected as new board members. Founder Dr Roy Hartvig Larsen steps down from the board to focus on new research projects.
ZGNX: 8.18 (-0.54)
Zogenix reports 1Q loss
Automated Insights - Tue May 10, 4:20PM CDT
EMERYVILLE, Calif. (AP) _ Zogenix Inc. (ZGNX) on Tuesday reported a loss of $10.4 million in its first quarter.
ZGNX: 8.18 (-0.54)
Zogenix Provides Corporate Update and Reports First Quarter 2016 Financial Results
GlobeNewswire - Tue May 10, 3:01PM CDT
Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today provided a corporate update and announced financial results for the first quarter ended March 31, 2016.
ZGNX: 8.18 (-0.54)
Zogenix Announces New Efficacy and Safety Data on ZX008 for Treatment of Seizures in Dravet Syndrome
GlobeNewswire - Thu May 05, 7:01AM CDT
Patient and Caregiver Sleep Quality and Quality of Life Data Reported for First Time
ZGNX: 8.18 (-0.54)
Zogenix to Release First Quarter 2016 Financial Results and Host Conference Call and Webcast on May 10
GlobeNewswire - Tue May 03, 7:00AM CDT
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter ended March 31, 2016 after the market close, and will host a corporate update conference call and webcast on Tuesday, May 10, at 4:30 PM Eastern Time.
ZGNX: 8.18 (-0.54)
New Data on Zogenix's ZX008 for Dravet Syndrome to be Presented at 14th International Child Neurology Congress
GlobeNewswire - Thu Apr 21, 7:03AM CDT
Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that new data on ZX008 (low-dose fenfluramine) will be presented at the 14 International Child Neurology Congress (ICNC), which will take place in Amsterdam, The Netherlands, from May 1 - 5, 2016. The presentation will report the latest efficacy and safety data from the prospectively followed cohort of patients treated with ZX008 for Dravet syndrome, a rare and catastrophic form of childhood epilepsy. In addition, for the first time, data will be presented on patient and caregiver sleep quality and quality of life.
ZGNX: 8.18 (-0.54)
Commit To Buy Zogenix At $8, Earn 8.1% Annualized Using Options
StockOptionsChannel.com - Tue Apr 12, 10:38AM CDT
Investors eyeing a purchase of Zogenix Inc. shares, but tentative about paying the going market price of $10.31/share, might benefit from considering selling puts among the alternative strategies at their disposal.
ZGNX: 8.18 (-0.54)
Cipher Pharmaceuticals Proposes Adding Rosemary A. Crane and Dr. Renee P. Tannenbaum To Board of Directors
CNW Group - Thu Apr 07, 6:00AM CDT
Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company"
today announced that Rosemary A. (Rose) Crane and Dr. Renee P. Tannenbaum, two pharmaceutical industry leaders, are being proposed for election to Cipher's Board of Directors at the Company's Annual and Special Meeting on May 5, 2016.
CPH.TO: 5.46 (-0.12), MELA: 1.12 (+0.01), ZGNX: 8.18 (-0.54), CPHR: 4.39 (+0.08), ABBV: 64.03 (-0.07), TEVA: 50.90 (+0.51)
Zogenix to Participate in LEERINK Partners 5th Annual Global Healthcare Conference
GlobeNewswire - Wed Feb 03, 7:00AM CST
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, and Bradley S. Galer, M.D., Executive Vice President and CMO, will present a corporate update at the LEERINK Partners 5 Annual Global Healthcare Conference in New York, NY, on February 10, 2016.
ZGNX: 8.18 (-0.54)
Bipolar Disorder (Manic Depression) - Pipeline Review
M2 - Mon Feb 01, 4:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/f9ppsp/bipolar_disorder) has announced the addition of the "Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Bipolar Disorder (Manic Depression) Overview - Therapeutics Development - Pipeline Products for Bipolar Disorder (Manic Depression) - Overview - Pipeline Products for Bipolar Disorder (Manic Depression) - Comparative Analysis - Bipolar Disorder (Manic Depression) - Therapeutics under Development by Companies - Bipolar Disorder (Manic Depression) - Therapeutics under Investigation by Universities/Institutes - Bipolar Disorder (Manic Depression) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Bipolar Disorder (Manic Depression) - Products under Development by Companies - Bipolar Disorder (Manic Depression) - Products under Investigation by Universities/Institutes - Bipolar Disorder (Manic Depression) - Companies Involved in Therapeutics Development Companies Mentioned: - Aequus Pharmaceuticals Inc. - ANP Technologies, Inc. - AstraZeneca Plc - Convergence Pharmaceuticals Ltd. - D-Pharm Ltd. - Delpor, Inc. - Intas Pharmaceuticals Ltd. - Intra-Cellular Therapies, Inc. - Johnson & Johnson - KemPharm, Inc. - Neurocrine Biosciences, Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Reviva Pharmaceuticals Inc. - SK Biopharmaceuticals Co., Ltd. - Sumitomo Dainippon Pharma Co., Ltd. - Teva Pharmaceutical Industries Limited - Zogenix, Inc. - Zysis Limited For more information visit http://www.researchandmarkets.com/research/f9...r_disorder
JNJ: 119.08 (-0.26), NBIX: 50.12 (+1.66), KMPH: 4.44 (+0.12), ZGNX: 8.18 (-0.54), PFE: 34.68 (-0.12), AZN: 32.60 (-0.21), TEVA: 50.90 (+0.51), ITCI: 40.63 (+0.29), OMER: 10.76 (+0.02)
Will Insiders Be Tempted To Buy More ZGNX At The New 52-Week Low?
TheOnlineInvestor.com - Wed Jan 20, 12:14PM CST
In trading on Wednesday, shares of Zogenix Inc. touched a new 52-week low of $9.02/share.
ZGNX: 8.18 (-0.54)
Zogenix Receives Fast Track Designation From FDA for Development of ZX008 in Dravet Syndrome
GlobeNewswire - Tue Jan 19, 7:09AM CST
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for the development program for the Company's investigational product, ZX008, as a treatment of seizures associated with Dravet syndrome, a rare and catastrophic form of childhood epilepsy.
ZGNX: 8.18 (-0.54)
Zogenix, Inc Gained 29% in 2015 -- Here's Why
Brian Feroldi, The Motley Fool - Motley Fool - Thu Jan 14, 10:59AM CST
What: 2015 was a great year to be a Zogenix shareholder. The clinical-stage biopharmaceutical company's stock soared more than 29% higher during the year, according to data from S&P Capital IQ . So what: The year was filled with...
PTX: 0.59 (-0.05), ZGNX: 8.18 (-0.54)
Healthcare Sector Equities under Review -- Amarin, Arrowhead Research, Zogenix, and PetMed Express
ACCESSWIRE - Wed Jan 13, 7:02AM CST
NEW YORK, NY / ACCESSWIRE / January 13, 2016 / Park Lane Advisor has initiated coverage on the following equities: Amarin Corporation PLC (NASDAQ: AMRN), Arrowhead Research Corporation (NASDAQ: ARWR), Zogenix Inc. (NASDAQ: ZGNX), and PetMed Express Inc. (NASDAQ: PETS). Free research report on Amarin can be accessed at http://www.parklaneadvisor.com/ On Tuesday, January 12, 2016, the NASDAQ Composite ended at 4,685.92, up 1.03%, the Dow Jones Industrial Average advanced 0.72%, to finish the day at 16,516.22, and the S&P 500 closed at 1,938.68, up 0.78%. The gains were broad based as six out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
PETS: 20.19 (+0.03), ARWR: 7.06 (+0.13), ZGNX: 8.18 (-0.54), AMRN: 2.79 (-0.01)
Zogenix Announces Initiation of Phase 3 Program for ZX008 in Dravet Syndrome
GlobeNewswire - Mon Jan 11, 7:00AM CST
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced the initiation of the first Phase 3 clinical trial for the Company's lead product candidate, ZX008, as an adjunctive treatment of seizures in children with Dravet syndrome.
ZGNX: 8.18 (-0.54)
Zogenix Provides Corporate Update and Reports Second Quarter 2016 Financial Results
GlobeNewswire - Tue Aug 09, 3:01PM CDT
Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today provided a corporate update and announced financial results for the second quarter ended June 30, 2016.
ZGNX: 8.18 (-0.54)
Zogenix to Release Second Quarter 2016 Financial Results and Host Conference Call and Webcast on August 9
GlobeNewswire - Tue Aug 02, 7:00AM CDT
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that it will report its financial results for the second quarter ended June 30, 2016 after the market close, and will host a corporate update conference call and webcast on Tuesday, August 9, at 4:30 PM Eastern Time.
ZGNX: 8.18 (-0.54)
Zogenix Announces Initiation of Multi-National Phase 3 Clinical Trial for ZX008 in Dravet Syndrome
GlobeNewswire - Tue Jun 07, 7:00AM CDT
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced the initiation of the second Phase 3 clinical trial, a multi-national study (Study 1502), for the Company's lead product candidate, ZX008, as an adjunctive treatment of seizures in children with Dravet syndrome. ZX008 is designated as an orphan drug in both the U.S. and Europe, and received Fast Track designation in the U.S., for the treatment of Dravet syndrome.
ZGNX: 8.18 (-0.54)
Zogenix to Participate in Jefferies 2016 Healthcare Conference
GlobeNewswire - Tue May 31, 7:00AM CDT
Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, will present a corporate update at the Jefferies 2016 Healthcare Conference, which is being held in New York, NY, June 7-10, 2016.
ZGNX: 8.18 (-0.54)
Nordic Nanovector ASA: New Board Members Elected Bringing Further Expertise in the Development and Commercialization of Innovative Cancer Therapies
BusinessWire - Mon May 23, 12:17AM CDT
The annual general meeting of Nordic Nanovector ASA on 19 May elected two new board members, further strengthening the base of international experience as well as oncology/haematology, life science and commercialization expertise of the company's board. Dr Renee P Tannenbaum, Pharm. D and Jean-Pierre Bizzari, MD, were elected as new board members. Founder Dr Roy Hartvig Larsen steps down from the board to focus on new research projects.
ZGNX: 8.18 (-0.54)
Zogenix reports 1Q loss
Automated Insights - Tue May 10, 4:20PM CDT
EMERYVILLE, Calif. (AP) _ Zogenix Inc. (ZGNX) on Tuesday reported a loss of $10.4 million in its first quarter.
ZGNX: 8.18 (-0.54)
Zogenix Provides Corporate Update and Reports First Quarter 2016 Financial Results
GlobeNewswire - Tue May 10, 3:01PM CDT
Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today provided a corporate update and announced financial results for the first quarter ended March 31, 2016.
ZGNX: 8.18 (-0.54)
Zogenix Announces New Efficacy and Safety Data on ZX008 for Treatment of Seizures in Dravet Syndrome
GlobeNewswire - Thu May 05, 7:01AM CDT
Patient and Caregiver Sleep Quality and Quality of Life Data Reported for First Time
ZGNX: 8.18 (-0.54)
Zogenix to Release First Quarter 2016 Financial Results and Host Conference Call and Webcast on May 10
GlobeNewswire - Tue May 03, 7:00AM CDT
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter ended March 31, 2016 after the market close, and will host a corporate update conference call and webcast on Tuesday, May 10, at 4:30 PM Eastern Time.
ZGNX: 8.18 (-0.54)
New Data on Zogenix's ZX008 for Dravet Syndrome to be Presented at 14th International Child Neurology Congress
GlobeNewswire - Thu Apr 21, 7:03AM CDT
Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that new data on ZX008 (low-dose fenfluramine) will be presented at the 14 International Child Neurology Congress (ICNC), which will take place in Amsterdam, The Netherlands, from May 1 - 5, 2016. The presentation will report the latest efficacy and safety data from the prospectively followed cohort of patients treated with ZX008 for Dravet syndrome, a rare and catastrophic form of childhood epilepsy. In addition, for the first time, data will be presented on patient and caregiver sleep quality and quality of life.
ZGNX: 8.18 (-0.54)
Commit To Buy Zogenix At $8, Earn 8.1% Annualized Using Options
StockOptionsChannel.com - Tue Apr 12, 10:38AM CDT
Investors eyeing a purchase of Zogenix Inc. shares, but tentative about paying the going market price of $10.31/share, might benefit from considering selling puts among the alternative strategies at their disposal.
ZGNX: 8.18 (-0.54)
Cipher Pharmaceuticals Proposes Adding Rosemary A. Crane and Dr. Renee P. Tannenbaum To Board of Directors
CNW Group - Thu Apr 07, 6:00AM CDT
Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company"
today announced that Rosemary A. (Rose) Crane and Dr. Renee P. Tannenbaum, two pharmaceutical industry leaders, are being proposed for election to Cipher's Board of Directors at the Company's Annual and Special Meeting on May 5, 2016. CPH.TO: 5.46 (-0.12), MELA: 1.12 (+0.01), ZGNX: 8.18 (-0.54), CPHR: 4.39 (+0.08), ABBV: 64.03 (-0.07), TEVA: 50.90 (+0.51)
Zogenix to Participate in LEERINK Partners 5th Annual Global Healthcare Conference
GlobeNewswire - Wed Feb 03, 7:00AM CST
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, and Bradley S. Galer, M.D., Executive Vice President and CMO, will present a corporate update at the LEERINK Partners 5 Annual Global Healthcare Conference in New York, NY, on February 10, 2016.
ZGNX: 8.18 (-0.54)
Bipolar Disorder (Manic Depression) - Pipeline Review
M2 - Mon Feb 01, 4:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/f9ppsp/bipolar_disorder) has announced the addition of the "Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Bipolar Disorder (Manic Depression) Overview - Therapeutics Development - Pipeline Products for Bipolar Disorder (Manic Depression) - Overview - Pipeline Products for Bipolar Disorder (Manic Depression) - Comparative Analysis - Bipolar Disorder (Manic Depression) - Therapeutics under Development by Companies - Bipolar Disorder (Manic Depression) - Therapeutics under Investigation by Universities/Institutes - Bipolar Disorder (Manic Depression) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Bipolar Disorder (Manic Depression) - Products under Development by Companies - Bipolar Disorder (Manic Depression) - Products under Investigation by Universities/Institutes - Bipolar Disorder (Manic Depression) - Companies Involved in Therapeutics Development Companies Mentioned: - Aequus Pharmaceuticals Inc. - ANP Technologies, Inc. - AstraZeneca Plc - Convergence Pharmaceuticals Ltd. - D-Pharm Ltd. - Delpor, Inc. - Intas Pharmaceuticals Ltd. - Intra-Cellular Therapies, Inc. - Johnson & Johnson - KemPharm, Inc. - Neurocrine Biosciences, Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Reviva Pharmaceuticals Inc. - SK Biopharmaceuticals Co., Ltd. - Sumitomo Dainippon Pharma Co., Ltd. - Teva Pharmaceutical Industries Limited - Zogenix, Inc. - Zysis Limited For more information visit http://www.researchandmarkets.com/research/f9...r_disorder
JNJ: 119.08 (-0.26), NBIX: 50.12 (+1.66), KMPH: 4.44 (+0.12), ZGNX: 8.18 (-0.54), PFE: 34.68 (-0.12), AZN: 32.60 (-0.21), TEVA: 50.90 (+0.51), ITCI: 40.63 (+0.29), OMER: 10.76 (+0.02)
Will Insiders Be Tempted To Buy More ZGNX At The New 52-Week Low?
TheOnlineInvestor.com - Wed Jan 20, 12:14PM CST
In trading on Wednesday, shares of Zogenix Inc. touched a new 52-week low of $9.02/share.
ZGNX: 8.18 (-0.54)
Zogenix Receives Fast Track Designation From FDA for Development of ZX008 in Dravet Syndrome
GlobeNewswire - Tue Jan 19, 7:09AM CST
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for the development program for the Company's investigational product, ZX008, as a treatment of seizures associated with Dravet syndrome, a rare and catastrophic form of childhood epilepsy.
ZGNX: 8.18 (-0.54)
Zogenix, Inc Gained 29% in 2015 -- Here's Why
Brian Feroldi, The Motley Fool - Motley Fool - Thu Jan 14, 10:59AM CST
What: 2015 was a great year to be a Zogenix shareholder. The clinical-stage biopharmaceutical company's stock soared more than 29% higher during the year, according to data from S&P Capital IQ . So what: The year was filled with...
PTX: 0.59 (-0.05), ZGNX: 8.18 (-0.54)
Healthcare Sector Equities under Review -- Amarin, Arrowhead Research, Zogenix, and PetMed Express
ACCESSWIRE - Wed Jan 13, 7:02AM CST
NEW YORK, NY / ACCESSWIRE / January 13, 2016 / Park Lane Advisor has initiated coverage on the following equities: Amarin Corporation PLC (NASDAQ: AMRN), Arrowhead Research Corporation (NASDAQ: ARWR), Zogenix Inc. (NASDAQ: ZGNX), and PetMed Express Inc. (NASDAQ: PETS). Free research report on Amarin can be accessed at http://www.parklaneadvisor.com/ On Tuesday, January 12, 2016, the NASDAQ Composite ended at 4,685.92, up 1.03%, the Dow Jones Industrial Average advanced 0.72%, to finish the day at 16,516.22, and the S&P 500 closed at 1,938.68, up 0.78%. The gains were broad based as six out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
PETS: 20.19 (+0.03), ARWR: 7.06 (+0.13), ZGNX: 8.18 (-0.54), AMRN: 2.79 (-0.01)
Zogenix Announces Initiation of Phase 3 Program for ZX008 in Dravet Syndrome
GlobeNewswire - Mon Jan 11, 7:00AM CST
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced the initiation of the first Phase 3 clinical trial for the Company's lead product candidate, ZX008, as an adjunctive treatment of seizures in children with Dravet syndrome.
ZGNX: 8.18 (-0.54)
